Key takeaways
Inpefa (sotagliflozin) and Farxiga (dapagliflozin) are both medications used to help with heart-related issues and chronic kidney disease (CKD). They belong to a class of medications called sodium-glucose cotransporter (SGLT) inhibitors, but they work a bit differently. Inpefa is an SGLT1/SGLT2 inhibitor, which means it blocks sugar and sodium absorption in both the kidneys and the gut. Farxiga, on the other hand, is an SGLT2 inhibitor that works only in the kidneys. Inpefa is taken once daily before breakfast, while Farxiga can be taken once daily at any time of the day. Inpefa is not approved to treat diabetes directly, but it helps lower heart risks in people with Type 2 diabetes. Farxiga is approved to lower blood sugar in people with Type 2 diabetes and can be used by children 10 years and older. Inpefa is a newer medication without a generic version, while Farxiga has a cheaper generic available. Both medications can cause urinary tract infections, yeast infections, and increased urination, but Inpefa may also cause diarrhea. Both medications can interact with other diabetes medications, increasing the risk of low blood sugar.
